Valora Therapeutics’ antibody lectin chimeras, or AbLecs, target glyco-immune checkpoints, pathways that modulate cellular communication with the immune system. The startup’s science is based on research from Carolyn Bertozzi, a Stanford professor who was awarded the 2022 Nobel Prize in Chemistry.
The biotech company will have the exclusive option to buy the remainder of the company, while Pionyr's shareholders will be entitled to up to nearly $1.5 billion in option exercise fees and milestone payments.
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Two drugs - Pfizer and Merck KGaA's Bavencio and AstraZeneca's Imfinzi - saw Phase III trials fail, while anticipated negative results prompted Roche to withdraw Tecentriq from regulatory review.
Data from the Phase III MYSTIC study showed Imfinzi and tremelimumab did not extend survival in first-line NSCLC. AstraZeneca's shares were down on the news.
Immuno-oncology is on a roll, yet many questions remain unanswered. What incites an immune response and where does the future of the field lie?
Checkpoint Pharmaceuticals wants to advance a drug that boosts immune activity to make checkpoint inhibitors work better.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.